ncRNA name
hsa-miR-26b
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
ATF2
Cancer name
Laryngeal Cancer
Cancer site
Larynx
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
However, overexpression of miR-26b significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to Hep-2/R.
Tissue resource
human laryngeal cancer cell lines Hep-2
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Shanghai Institute for Biological Sciences, Chinese Academy of Sciences
Country
China
Continent
Asia